Case-Control Studies Humans Male NAD(P)H Dehydrogenase (Quinone)/*genetics Polymorphism Single Nucleotide Prostatic Neoplasms/*genetics Urinary Bladder Neoplasms/*genetics NQO1 gene meta-analysis polymorphism prostatic neoplasms urinary bladder neoplasms

Bcg Bladder cancer Covid-19 Coronavirus

Carcinogenesis/genetics/*immunology/pathology *Genetic Predisposition to Disease Humans Inflammation/genetics/*immunology/pathology *Polymorphism Single Nucleotide Receptors Interleukin/*genetics Urinary Bladder Neoplasms/genetics/*immunology/pathology Bladder urothelial carcinoma Gene polymorphism Interleukin 17 Interleukin 23 Interleukin-23 receptor Natural killers Tumour-associated macrophages

T1G3膀胱癌 根治性膀胱切除术 保留膀胱

Endoscopic bladder cancer follow-up surveillance form (available at http://dx.doi.org/10.21037/tau-20-1363). The series “Expectant Management in Genitourinary Malignancies (Prostate Bladder Kidney)” was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare.

Quality of life (QoL) bladder cancer non-muscle invasive bladder cancer (NMIBC) surveillance form (available at http://dx.doi.org/10.21037/tau-20-1333). The series “Expectant Management in Genitourinary Malignancies (Prostate Bladder Kidney)” was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare.

Urinary bladder neoplasms adjuvant chemotherapy meta-analysis neoadjuvant chemotherapy (NAC) form (available at http://dx.doi.org/10.21037/tau-20-571). Dr. XZ serves as an unpaid editorial board member of Translational Andrology and Urology from Mar 2015 to Feb 2021. The other authors have no conflicts of interest to declare.

长链非编码RNA 尿路上皮癌相关1基因 膀胱癌 诊断 Meta分析

Adult Caffeine/*adverse effects Central Nervous System Stimulants/adverse effects Coffee/*adverse effects Cytochrome P-450 CYP1A2 Dose-Response Relationship Drug Female Humans Male Middle Aged Risk Factors Smoking/*adverse effects Urinary Bladder Neoplasms/*etiology Bladder cancer Coffee consumption Cohort study Dose–response analyses Smoking

Adult Aged Aged 80 and over B7-H1 Antigen/genetics/*immunology Female Humans Immune Checkpoint Inhibitors/*administration & dosage *Immunotherapy Male Middle Aged Programmed Cell Death 1 Receptor/genetics/*immunology Progression-Free Survival Randomized Controlled Trials as Topic Treatment Outcome Urinary Bladder Neoplasms/genetics/immunology/mortality/*therapy efficacy immunotherapy meta-analysis safety urothelial cancer this study.

Guidelines as Topic Humans Immunotherapy/*methods Societies Medical/*standards Urinary Bladder Neoplasms/*drug therapy antineoplastic protocols immunotherapy urinary bladder neoplasms urologic neoplasms Pfizer AstraZeneca Nektar Seattle Genetics DragonFly Therapeutics Non-CME services: Genentech AstraZeneca Merck Seattle Genetics Contracted research: Genentech Merck AstraZeneca Nektar Seattle Genetics Immunomedics. PCB─Consulting fees: AbbVie Asieris Pharmaceuticals Astellas AstraZeneca Bayer Biosyent Bristol-Myers Squibb EMD Serono Ferring Fergene H3 Biomedicine Janssen Merck Roche Sanofi TerSera Urogen Contracted research: iProgen. MTC─Consulting fees: Pfizer EMD Serono AstraZeneca Exelixis Eisai Seattle Genetics Astellas Contracted research: Exelixis Pfizer/EMD Serono Janssen Apricity Health. GSD─Participant/unpaid volunteer: HealthVibe focus group 2020. MDG─Consulting fees: Inovio NuMab Janssen Merck GlaxoSmithKline Genentech Bristol-Myers Squibb Seattle Genetics Dracen Dragonfly Astellas Novartis Pfizer AstraZeneca Incyte Dendreon Eli Lilly EMD Serono Aileron Therapeutics Ownership interest: Rappta Therapeutics NPI: 1639140668. PG─Consulting fees: AstraZeneca Dyania Health EMD Serono Immunomedics Janssen Merck Mirati Therapeutics Genentech Pfizer Seattle Genetics Contracted Research: Bavarian Nordic Bristol-Myers Squibb Clovis Oncology Debiopharm Immunomedics Pfizer Merck QED Therapeutics GlaxoSmithKline Kure It Cancer Research Mirati Therapeutics. SG─Consulting fees: Merck Bristol-Myers Squibb Janssen Seattle Genetics AstraZeneca Contracted research: Bristol-Myers Squibb Pfizer Non-CME services: Exelixis. CJH─Consulting fees: Astellas Bristol-Myers Squibb Genentech Merck Eisai Seattle Genetics 2bPrecise Non-CME services: Astellas Bristol-Myers Squibb Genentech Eisai Seattle Genetics. AMK─Consulting fees: Abbott Molecular Arquer ArTara Asieris AstraZeneca BioClin Therapeutics Bristol-Myers Squibb Cepheid Cold Genesys Eisai Engene Inc. Ferring FerGene Imagin Janssen MDxHealth Medac Merck Pfizer Photocure ProTara Roviant Seattle Genetics Sessen Bio Theralase TMC Innovation US Biotest Contracted research: Adolor Bristol-Myers Squibb FKD Industries Heat Biologics Merck Photocure SWOG/NIH SPORE AIBCCR Clinical trials: FKD Merck Bristol-Myers Squibb Photocure SWOG Adolor Heat Biologics Laboratory research: NIH SPORE AIBCCR Educational grant: CEC Oncology Editorial board: European Urology Oncology Journal of Urology UroToday President of organization: International Bladder Cancer Network (IBCN) International Bladder Cancer Group (IBCG) IP Rights: CyPRIT (Cytokine Predictors of Response to Intravesical Therapy) Joint with UT MD Anderson Cancer Center. LPL─Consulting fees: Pfizer Advisory Nursing board 2018 Lecture/Speaker/Expert Panel: ASCO Bladder Program 2019 Pfizer learning day 2019 ASCO Bladder Program Panel Member and Faculty 2019 Pfizer Learning Day Speaker 2019 BCAN Webinar Faculty 11/2020. JJM─Consulting fees: AstraZeneca Ferring Janssen Nucleix Foundation Medicine Contracted research: Epizyme Tesaro Abbvie Teaching an endoscopy course: Olympus. ERP─Consulting fees: AstraZeneca Infinity Pharma Pfizer Flatiron Genentech Merck Seattle Genetics Contracted research: Astellas Bristol-Myers Squibb Genentech Merck. JER─Consulting fees: Merck Bristol-Myers Squibb AstraZeneca Astellas Seattle Genetics Boehringer Ingelheim Bayer Pfizer Roche/Genentech Mirati QED Therapeutics Janssen Pharmacyclics GlaxoSmithKline Contracted research/Clinical trial funding: Seattle Genetics Astellas Roche/Genentech Bayer AstraZeneca QED Therapeutics. NS─Consulting fees: Amgen Astellas AstraZeneca Bayer Bristol-Myers Squibb Dendreon Fergene Ferring Janssen Merck Myovant Nymox Pfizer Sanofi/Genzyme Sesen Bio Sun Pharma Tolmar. GDS─Consulting fees: Merck Janssen Ferring Bristol-Myers Squibb Pfizer Genentech Epivax Oncology AstraZeneca Fidia Cold Genesys EnGene Bio Aduro Biotech Dendreon FKD Therapies CiClomed Seattle Genetics Urogen PhotoCure. SITC staff: SMW—Shares owned: Pacific Biosciences Editas Medicine EG AK BL LL─Nothing to disclose.

Carcinoma Transitional Cell/epidemiology/*pathology Disease Progression Humans Neoplasm Invasiveness Neoplasm Recurrence Local/epidemiology Neoplasm Staging Prognosis Urinary Bladder Neoplasms/epidemiology/*pathology Bladder cancer Progression Staging Substage T1 Urothelial carcinoma pT1

Adult Aged Aged 80 and over Female Humans Male Middle Aged Urinary Bladder Neoplasms/*radiotherapy Bladder neoplasm Bladder preservation Cis Chemoradiotherapy Radiotherapy T1 Bladder cancer

Cancer-specific survival Cystectomy T1G3 bladder cancer

Metabolic syndrome (MS) bladder cancer (BC) grade meta-analysis stage form (available at http://dx.doi.org/10.21037/tcr-20-3350). The authors have no conflicts of interest to declare.

膀胱癌 lncRNA UCA1 Meta分析

Antibodies Monoclonal/adverse effects/therapeutic use Antibodies Monoclonal Humanized/adverse effects/therapeutic use Antineoplastic Agents Immunological/*therapeutic use B7-H1 Antigen/*antagonists & inhibitors Clinical Trials Phase III as Topic Humans Network Meta-Analysis Programmed Cell Death 1 Receptor/*antagonists & inhibitors Salvage Therapy/*methods Survival Analysis Treatment Outcome Urinary Bladder Neoplasms/*drug therapy/*secondary PD-1 inhibitor PDL-1 inhibitor atezolizumab pembrolizumab urothelial bladder cancer

25-Hydroxyvitamin D3 1-alpha-Hydroxylase/metabolism Cell Line Tumor Humans Receptors Calcitriol/metabolism Risk Factors Signal Transduction Urinary Bladder Neoplasms/*blood/etiology/metabolism Vitamin D/*analogs & derivatives/blood/metabolism Vitamin D Deficiency/*blood/complications/metabolism 1 25(oh)(2)d 1α-hydroxylase Bladder cancer Cathelicidin Vitamin D

B7-H1 Antigen/*metabolism Biomarkers Tumor/metabolism Carcinoma Transitional Cell/metabolism/*mortality/pathology Cell Membrane/metabolism Gene Expression Regulation Neoplastic Humans Neoplasm Staging Prognosis Survival Analysis *Up-Regulation Urinary Bladder Neoplasms/metabolism/*mortality/pathology Biomarker Meta-analysis Pd-l1 Urothelial carcinoma

*Genetic Association Studies *Genetic Predisposition to Disease Genotype Glutathione Transferase/*genetics Humans Odds Ratio *Polymorphism Genetic Publication Bias Risk Urinary Bladder Neoplasms/*genetics Bladder cancer Gstm1 Gstp1 Gstt1 Gene polymorphism Meta-analysis PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.